TiGenix NV (NYSE: TIG) is a European cell therapy company with an advanced clinical stage pipeline of adult stem cell programs, and a commercialized product. The stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency. For more information, visit the company’s website at www.tigenix.com.